Xlumena has obtained the US Food and Drug Administration (FDA) approval to market its Axios stent and delivery system, through the FDA’s less-stringent de novo review pathway.
The stent is reportedly the first specifically designed device for the drainage of a pancreatic pseudocyst by creating a new, temporary opening between the pancreas and the gastrointestinal tract.
The Axios stent is a wire mesh tube with a silicone covering is tightly compressed and is enclosed within a catheter (a long, hollow, flexible tube), the Axios delivery system.
With the Axios stent, the catheter is placed into the stomach through an endoscope that is passed through the patient’s mouth and down into an area of the stomach adjacent to the pseudocyst.
Unlike plastic stents that are currently on the market, the stent may be less prone to becoming blocked by solid material inside of the pseudocyst because of its wider diameter.
The Axios stent can expand to more than 1/2in diameter, allowing physicians to pass endoscopic tools into the pseudocyst to clean or remove the contents of both the stent and the pseudocyst.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
It is fully covered to prevent leakage across the stent and tissue ingrowth and facilitates easy removal.
The Axios stent comes pre-loaded in a specially-designed delivery system and is easily deployed by a single operator.
According to the FDA, the approval was based on a 33-patient study of subjects with pancreatic pseudocysts of at least 6cm in diameter.
Trial data showed that the stent was successfully placed 90.0% of the time, with 97% of those staying in place for the duration of treatment (up to 60 days).
Around 93% of the stents remained open to allow for drainage of the pseudocyst for the duration of treatment, and 86% of the treated pseudocysts decreased in size by at least 50%.
All stents were removed without injury to the surrounding tissue. Adverse events observed included abdominal pain, nausea and vomiting.
FDA’s Center for Devices and Radiological Health Office of Device Evaluation director Christy Foreman said: "The Axios Stent provides a new option for physicians to effectively treat pseudocysts with a less invasive intervention than surgical removal of the pseudocyst."